| 1. |
- Rajasekaran, B., et al.
(author)
-
Influence of microarc oxidation and hard anodizing on plain fatigue and fretting fatigue behaviour of Al-Mg-Si alloy
- 2008
-
In: Surface & Coatings Technology. - 0257-8972 .- 1879-3347. ; 202:8, s. 1462-1469
-
Journal article (peer-reviewed)abstract
- The present study compares the performance of microarc oxidation (MAO) and hard anodizing (HA) treated Al-Mg-Si alloy (AA6063) test samples under cyclic loading in uniaxial tension with a stress ratio of 0.1 (plain fatigue) and fretting fatigue loading. Fatigue test specimens were treated using MAO and HA techniques. MAO coated specimens were ground to reduce the surface roughness comparable with that in HA coated specimens. In that process the porous outer layer was removed. Characterization of coated and uncoated specimens was done with reference to the coating morphology, microhardness, surface roughness and residual stress. The specimens were tested under plain fatigue and fretting fatigue loading at ambient temperature. While the ground MAO coating exhibited relatively less amount of porosity, HA coating had through thickness cracks. MAO coating had compressive residual stress and it was very hard compared with HA coating. Both types of coated samples exhibited slightly higher friction force than that experienced by the uncoated specimens. Fretted region of the HA coated samples was rougher than that of the MAO coated specimens. Plain fatigue lives of both coated samples were inferior to those of the uncoated specimens. The inferior plain fatigue lives of MAO coated specimens compared with those of the substrate may be attributed to the tensile residual stresses supposedly present in the substrate leading to an early crack initiation in the substrate adjacent to the coating. As friction force of MAO coated samples was higher than that experienced by uncoated specimens, the fretting fatigue lives of MAO coated samples were slightly inferior to those of uncoated samples. As the anodized layer had preexisting through thickness cracks and strong adhesion with the substrate, cracks propagated from HA coating through the interface into the substrate easily. This may be the reason for the HA coated samples exhibiting inferior plain fatigue and fretting fatigue lives compared with MAO coated and uncoated samples. © 2007 Elsevier B.V. All rights reserved.
|
|
| 2. |
- Sur, Dipika, et al.
(author)
-
Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial.
- 2009
-
In: Lancet. - 1474-547X. ; 374:9702, s. 1694-702
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Oral cholera vaccines consisting of killed whole cells have been available for many years, but they have not been used extensively in populations with endemic disease. An inexpensive, locally produced oral killed-whole-cell vaccine has been used in high-risk areas in Vietnam. To expand the use of this vaccine, it was modified to comply with WHO standards. We assessed the efficacy and safety of this modified vaccine in a population with endemic cholera. METHODS: In this double-blind trial, 107 774 non-pregnant residents of Kolkata, India, aged 1 year or older, were cluster-randomised by dwelling to receive two doses of either modified killed-whole-cell cholera vaccine (n=52 212; 1966 clusters) or heat-killed Escherichia coli K12 placebo (n=55 562; 1967 clusters), both delivered orally. Randomisation was done by computer-generated sequence in blocks of four. The primary endpoint was prevention of episodes of culture-confirmed Vibrio cholerae O1 diarrhoea severe enough for the patient to seek treatment in a health-care facility. We undertook an interim, per-protocol analysis at 2 years of follow-up that included individuals who received two completely ingested doses of vaccine or placebo. We assessed first episodes of cholera that occurred between 14 days and 730 days after receipt of the second dose. This study is registered with ClinicalTrials.gov, number NCT00289224. FINDINGS: 31 932 participants assigned to vaccine (1721 clusters) and 34 968 assigned to placebo (1757 clusters) received two doses of study treatment. There were 20 episodes of cholera in the vaccine group and 68 episodes in the placebo group (protective efficacy 67%; one-tailed 99% CI, lower bound 35%, p<0.0001). The vaccine protected individuals in age-groups 1.0-4.9 years, 5.0-14.9 years, and 15 years and older, and protective efficacy did not differ significantly between age-groups (p=0.28). We recorded no vaccine-related serious adverse events. INTERPRETATION: This modified killed-whole-cell oral vaccine, compliant with WHO standards, is safe, provides protection against clinically significant cholera in an endemic setting, and can be used in children aged 1.0-4.9 years, who are at highest risk of developing cholera in endemic settings. FUNDING: Bill & Melinda Gates Foundation, Swedish International Development Cooperation Agency, Governments of South Korea, Sweden, and Kuwait.
|
|
